Compounders Research Compare

Atrium Therapeutics, Inc.(RNA)

Biotechnology · San Diego, CA

$7.94-0.04 (-0.44%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

San Diego, CA

511 employees

www.atriumtherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kathleen Gallagher

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T19:53:46.613Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:53:46.613Z.

Quote observation: 2026-10-06T19:50:43.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 135,733,276
Total debt · period ending 2026-06-30: 1,683,000
Cash · period ending 2026-06-30: 72,645,000
TTM free cash flow · period ending 2026-06-30: N/A

FMP input reference: 87d00981f6afc2d6fb42b8babadf75d30967326f42a5e12d4c63051d6ceded83

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RNA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

RNA Competitors' EV/FCF Ratio

Atrium Therapeutics, Inc.

Current

Market Cap

$135.73M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Organigram Global Inc.

Market Cap

$136.72M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KORU Medical Systems, Inc.

Market Cap

$138.03M

EV/FCF Ratio

504.73x

TTM Avg

1051.55x

3Y Avg

1051.55x

5Y Avg

1051.55x

Freenome, Inc.

Market Cap

$133.21M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immuneering Corporation

Market Cap

$138.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alpha Cognition Inc

Market Cap

$139.78M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeMD, Inc.

Market Cap

$131.30M

EV/FCF Ratio

N/A

TTM Avg

61.40x

3Y Avg

555.49x

5Y Avg

549.31x

Sutro Biopharma, Inc.

Market Cap

$140.16M

EV/FCF Ratio

N/A

TTM Avg

31.12x

3Y Avg

31.12x

5Y Avg

31.12x

Health Catalyst, Inc.

Market Cap

$130.79M

EV/FCF Ratio

18.39x

TTM Avg

24.01x

3Y Avg

24.01x

5Y Avg

24.01x

AirSculpt Technologies, Inc.

Market Cap

$130.86M

EV/FCF Ratio

240.14x

TTM Avg

151.93x

3Y Avg

133.72x

5Y Avg

94.60x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Atrium Therapeutics, Inc. (RNA)	$135.73M	N/A	N/A	N/A	N/A
Organigram Global Inc. (OGI)vs ›	$136.72M	N/A	N/A	N/A	N/A
KORU Medical Systems, Inc. (KRMD)vs ›	$138.03M	504.73x	1051.55x	1051.55x	1051.55x
Freenome, Inc. (FRNM)vs ›	$133.21M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$138.49M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.78M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMD)vs ›	$131.30M	N/A	61.40x	555.49x	549.31x
Sutro Biopharma, Inc. (STRO)vs ›	$140.16M	N/A	31.12x	31.12x	31.12x
Health Catalyst, Inc. (HCAT)vs ›	$130.79M	18.39x	24.01x	24.01x	24.01x
AirSculpt Technologies, Inc. (AIRS)vs ›	$130.86M	240.14x	151.93x	133.72x	94.60x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics